Ron Levy, MD, professor of Medicine at Stanford, recounts his experiences moving his discovery from the lab to the clinical setting and discusses the future of this cancer treatment. Wendy Harpham, a participant in the early clinical trials of Rituxan, the first FDA-approved monoclonal antibody for cancer treatment that Levy developed, provides a patient's perspective.
Subscribe to:
Post Comments (Atom)
1 comment:
Hello,
This is the perfect blog for anyone who wants to know about this topic. Monoclonal antibodies are proteins consisting of four polypeptide chains. which is uses the ability of the antibodies to bind to the cancer cells having the tumor antigens on their surface...
Drug Discovery
Post a Comment